An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease

Expert Opinion on Investigational Drugs

Volumn 18, Issue 8, 2009, Pages 1147-1168

  Imbimbo, Bruno P ^a  

^a Research and Development Department   (Italy)

Author keywords

amyloid; secretase; Alzheimer's disease; Non steroidal anti inflammatory drugs

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; APOLIPOPROTEIN E4 EPSILON; BETA SECRETASE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MECLOFENAMIC ACID; MELOXICAM; MEMANTINE; NABUMETONE; NAPROXEN; NEUROTROPHIN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIROXICAM; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COLON POLYPOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT DURATION; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR, ANIMAL; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; HUMANS; PEPTIDE FRAGMENTS; TREATMENT FAILURE;

EID: 68049118952     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903066780     Document Type: Review

References (120)

1. Doody RS. Cholinesterase inhibitors and memantine: best practices. CNS Spectr 2008;13(10 Suppl 16):34-5
2. Small SA, Duff K. Linking Aβ and tau in late-onset alzheimer's disease: a dual pathway hypothesis. Neuron 2008;60:534-42
3. Carulla N, Caddy GL, Hall DR, et al. Molecular recycling within amyloid fibrils. Nature 2005;436:554-8
4. Shankar GM, Li S, Mehta TH, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
5. Opar A. Mixed results for disease-modification strategies for Alzheimer's disease. Nat. Rev Drug Discov 2008;7:717-8
6. Weggen S, Czirr E, Leuchtenberger S, Eriksen J. Nonsteroidal anti-inflammatory drugs (NSAIDs) and derived Aβ42-lowering molecules for treatment and prevention of Alzheimer's disease (AD. In: Claudio A Cuello, editor, Pharmacological Mechanisms in Alzheimer's Therapeutics, Springer New York, 2007:167-93
7. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002;35:419-32
8. Blasko I, Veerhuis R, Stampfer-Kountchev M, et al. Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ-42 by human astrocytes. Neurobiol Dis 2000;7:682-9
9. Potter H, Wefes IM, Nilsson LN. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 2001;22:923-30
10. Hoozemans JJ, Rozemuller JM, van Haastert ES, et al. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 2008;14:1419-27
11. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998;47(Suppl 2):S78-87
12. Clevers H. Colon cancer-understanding how NSAIDs work. N Engl J Med 2006;354:761-3
13. Finckh A, Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann Intern Med 2005;142:212-4
14. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11
15. Couzin J. Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 2004;306:1673-5
16. Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2006;5:83-94
17. In T'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:515-21
18. Etminan M, Gill S, Samii A. Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128-32
19. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004;23:159-69
20. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008;70:1672-7
21. Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008;70:17-24
22. Hayden KM, Zandi PP, Khachaturian AS, et al. Cache County Investigators. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007;69:275-82
23. Cornelius C, Fastbom J, Winblad B, Viitanen M. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E ε4 allele in an elderly population. Neuroepidemiology 2004;23:135-43
24. Haag MD, van Oijen M, de Jong FJ, et al. Amyloid β42-level lowering non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease [abstract O2-06-04]. Alzheimers Dement 2006;2(Suppl 1):S43
25. Breteler MMB, In HET, Veld B, et al. Aβ-42 peptide lowering NSAIDs and Alzheimer's disease. Neurobiol Aging 2002;23:S286
26. Landi F, Cesari M, Onder G, et al Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiatry 2003;11:179-85
27. Szekely CA, Green RC, Breitner JC, et al. No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008;70:2291-8
28. de Craen AJ, Gussekloo J, Vrijsen B, Westendorp RG. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 2005;161:114-20
29. Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008;70:2219-25
30. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009;72:1899-905
31. Sung S, Yang H, Uryu K, et al. Modulation of NF-κB activity by indomethacin influences Aβ levels but not APP metabolism in a model of Alzheimer disease. Am J Pathol 2004;165:2197-206
32. Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of γ-secretase. J Neurosci 2003;23:9796-804
33. Mackenzie IR. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol Aging 2001;22:819-22
34. Halliday GM, Shepherd CE, McCann H, et al. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 2000;57:831-6
35. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001;414:212-6
36. Avramovich Y, Amit T, Youdim MB. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem 2002;277:31466-73
37. Thomas T, Nadackal TG, Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport 2001;12:3263-7
38. Sastre M, Dewachter I, Rossner S, et al. Nonsteroidal anti-inflammatory drugs repress γ secretase gene promoter activity by the activation of PPAR γ. Proc Natl Acad Sci USA 2006;103:443-8
39. Morihara T, Teter B, Yang F, et al. Ibuprofen suppresses interleukin-1β induction of pro-amyloidogenic β1-antichymotrypsin to ameliorate β-amyloid (Aβ) pathology in Alzheimer's models. Neuropsychopharmacology 2005;30:1111-20
40. Zhao X, Rebeck GW, Hoe HS, Andrews PM. Tarenflurbil protection from cytotoxicity is associated with an upregulation of neurotrophins. J Alzheimers Dis 2008;15:397-407
41. Morihara T, Chu T, Ubeda O, et al. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J Neurochem 2002;83:1009-12
42. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Invest 2003;112:440-9
43. Takahashi Y, Hayashi I, Tominari Y, et al. Sulindac sulphide is a noncompetitive γ secretase inhibitor that preferentially reduces Aβ42 generation. J Biol Chem 2003;278:18664-70
44. Gasparini L, Rusconi L, Xu H, et al. Modulation of β amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem 2004;88:337-48
45. Sainati SM, Ingram DM, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, Sweden, April 5-8, 2000. Abstract Book (p. 180)
46. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. JAMA 2003;289:2819-26
47. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23:8-21
48. Thal LJ, Ferris SH, Kirby L, et al. Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-15
49. Agdeppa ED, Kepe V, Petri A, et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl) (methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 2003;117:723-30
50. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. Neuropharmacology 2005;49:1088-99
51. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901
52. Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting γ-secretase modulators. Nature 2008;453:925-9
53. Lanz TA, Fici GJ, Merchant KM. Lack of specific Aβ(1-42) suppression by NSAIDs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 2005;312:399-406
54. Stock N, Munoz B, Wrigley JD, et al. The geminal dimethyl analogue of Flurbiprofen as a novel Aβ42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett 2006:16: 2219-23
55. Peretto I, Radaelli S, Parini C, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of β-amyloid1-42 secretion. J Med Chem 2005;48:5705-20
56. Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 2005;128:1442-53
57. Demattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-7
58. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003;23:7504-9
59. Lim GP, Yang F, Chen P, et al. Ibuprofen suppresses plaque pathology in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-14
60. Jantzen PT, Connor KE, Dicarlo G, et al. Microglial activation and β-amyloid deposit reduction caused by a nitric-oxide-releasing non-steroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-54
61. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001;22:983-91
62. Kotilinek LA, Westerman MA, Wang Q, et al. Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain 2008;131:651-64
63. Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nat Med 2005;11:545-50
64. McKee AC, Carreras I, Hossain L, et al. Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008;1207:225-36
65. Imbimbo B, Hutter-Paier B, Villetti G, et al. CHF5074, a novel γ-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 2009;156:982-93
66. Quinn J, Montine T, Morrow J, et al. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 2003;137:32-41
67. Kukar T, Prescott S, Eriksen JL, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007;8:54-65
68. van Groen T, Kadish I. Transgenic AD. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Brain Res Rev 2005:48:370-8
69. Wilcock DM, Jantzen PT, Li Q, et al. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 2007;144:950-60
70. Melnikova T, Savonenko A, Wang Q, et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006;141:1149-62
71. Czirr E, Leuchtenberger S, Dorner-Ciossek C, et al. Insensitivity to Aβ42-lowering nonsteroidal anti-inflammatory drugs and γ-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Chem 2007;282:24504-13
72. Lleo A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation. Nat Med 2004;10:1065-6
73. Van Dam D, Coen K, De Deyn P. Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. J Psychopharmacol 2008 Nov 21 [Epub ahead of print]
74. Sagi SA, Weggen S, Eriksen J, et al. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of κB kinase, and NFκB, do not reduce amyloid β42 production. J Biol Chem 2003;278:31825-30
75. Zhou Y, Su Y, Li B, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science 2003;302:1215-7
76. Leuchtenberger S, Kummer MP, Kukar T, et al. Inhibitors of Rho-kinase modulate amyloid-β (Aβ) secretion but lack selectivity for Aβ42. J Neurochem 2006;96:355-65
77. Weggen S, Eriksen JL, Sagi SA, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity. J Biol Chem 2003;278:31831-7
78. Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004;279:43419-26
79. Berezovska O, Lleo A, Herl LD, et al. Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 2005;25:3009-17
80. Beher D, Graham SL. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. Expert Opin Investig Drugs 2005;14:1385-1409
81. Fraering PC, Ye W, Strub JM, et al. Purification and characterization of the human γ-secretase complex. Biochemistry 2004;43:9774-89
82. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatr 1994;151:1105-13
83. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11
84. de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS ONE 2008;3:e1475
85. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201
86. Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002;58:1050-4
87. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000;54:588-93
88. Van Gool WA, Weinstein HC, Scheltens P, et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18 month randomised, double-blind, placebo-controlled study. Lancet 2001;358:455-60
89. McGeer PL, Harada N, Kimura H, et al. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 1992;3:146-9
90. Bain A. Alzheimer disease: Dapsone Phase 2 trial results reported. Immune Network Ltd press release, October 15 2002
91. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71
92. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93
93. Imbimbo BP. Why did tarenflurbil fail in Alzheimer's disease? J Alzheimers Dis 2009. In press
94. Green RC, Schneider LS, Hendrix SB, et al. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multi-center Phase 3 trial. Alzheimers Dement 2008;4(Suppl 2):T165.
95. 11th International Conference on Alzheimer's Disease. Chicago, Illinois, July 26-31, 2008. Oral Session O3-04, Drug Discovery: Clinical Trials. A.V.E.R. Associates, Eldridge, Maryland (http://conferencerecordings.com)
96. Gómez-isla T, Blesa R, Boada M, et al. TRIMCI Study Group. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord 2008;22:21-9
97. Small GW, Siddarth P, Silverman DH, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am J Geriatr Psychiatry 2008;16:999-1009
98. Lyketsos CG, Breitner JC, Green RC, et al. ADAPT Research Group Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007;68:1800-8
99. Martin BK, Szekely C, Brandt J, et al. ADAPT Research Group. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008;65:896-905
100. Breitner JC. Treatment effects of NSAIDs related to stage of Alzheimer's disease pathogenesis. Lessons from ADAPT. 12th International Conference on Alzheimer's Disease, Vienna, July 11-16, 2009. Abstract S4-02-03
101. Masters CL, Wyss-Coray T, Giulio Pasinetti GM. Anti-inflammatory drugs fall short in Alzheimer's disease. Nat Med 2008;14:916
102. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar γ-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005;25:8240-9
103. Boche D, Nicoll JA. The role of the immune system in clearance of Aβ from the brain. Brain Pathol 2008;18:267-78
104. Simard AR, Soulet D, Gowing G, et al. Bone marrow derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006;49:489-502
105. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007;13:432-8
106. Mandrekar S, Jiang Q, Lee CY, et al. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 2009;29:4252-62
107. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: The dual role of microglia. Neuroscience 2009;158:1021-9
108. Olah M, Ping G, De Haas AH, et al. Enhanced hippocampal neurogenesis in the absence of microglia T cell interaction and microglia activation in the murine running wheel model. Glia 2008;57:1046-61
109. Thored P, Heldmann U, Gomes-Leal W, et al. Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia 2008 ;57:835-49
110. Cacci E, Ajmone-Cat MA, Anelli T, et al. In vitro neuronal and glial differentiation from embryonic or adult neural precursor cells are differently affected by chronic or acute activation of microglia. Glia 2008;56:412-25
111. Sasaki T, Kitagawa K, Sugiura S, et al. Implication of cyclooxygenase-2 on enhanced proliferation of neural progenitor cells in the adult mouse hippocampus after ischemia. J Neurosci Res 2003;72:461-71
112. Imbimbo BP. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs 2004;13:1469-81
113. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44
114. Dvir E, Friedman JE, Lee JY, et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p- chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]butanoyl}-sn-glycero-3- phosophatidyl choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J Pharmacol Exp Ther 2006;318:1248-56
115. Richardson RL, Kim EM, Shephard RA, et al. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ(1-42) injections in the rat. Brain Res 2002;954:1-10
116. Browne KD, Iwata A, Putt ME, Smith DH. Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats. Exp Neurol 2006;201:301-7
117. Jin DQ, Sung JY, Hwang YK, et al. Dexibuprofen (S(+)-isomer ibuprofen) reduces microglial activation and impairments of spatial working memory induced by chronic lipopolysaccharide infusion. Pharmacol Biochem Behav 2008;89:404-11
118. Mesches MH, Gemma C, Veng LM, et al. Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. Neurobiol Aging 2004;25:315-24
119. Hauss-Wegrzyniak B, Vraniak P, Wenk GL. The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol Aging 1999;20:305-13
120. Joo Y, Kim HS, Woo RS, et al. Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol Pharmacol 2006;69:76-84